chemieunternehmen.com

Evotec SE announced today that the Company has received a US$ 2.5 m grant from the Bill & Melinda Gates Foundation (“the foundation”) for its teratogenicity platform, and joins the foundation’s prestigious Global Health Discovery Collaboratory (“GHDC”), a network of researchers, centres of excellence, and technology platforms working together to accelerate the discovery and translation of global health interventions. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-us-25-m-grant-to-leverage-human-ipsc-derived-teratogenicity-platform-for-global-health-programmes-6356

Evotec SE announced today that the Company has entered a partnership with Charité – Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis (“AAV”), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-partnership-with-charite-to-expand-molecular-patient-database-in-autoimmune-diseases-6354

Evotec SE announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd (“Jingxin”) has received the approval from the Chinese National Medical Products Administration (“NMPA”) for the novel insomnia treatment EVT201, also known as Dimdazenil in China.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-jingxin-receives-approval-for-evt201-in-china-6352

Evotec SE today announced the expansion of its $ 20 m beLAB1407 BRIDGE partnership with Bristol Myers Squibb to include the Universities of Bristol and Glasgow as well as Queen Mary University of London. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-belab1407-bridge-partnership-with-bristol-myers-squibb-to-include-3-new-university-partners-6350

Evotec SE announces that a video recording of the Capital Markets Day presentations is now available. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-video-recording-of-capital-markets-day-presentations-published-6348

Evotec SE today presents at its Capital Markets Day how the Company is driving more efficient pipeline building towards assets, that are progressing with higher probabilities of success. Evotec’s platforms leverage novel A.I.-powered technologies that lead to new opportunities, higher capital efficiency, and ultimately improved patient outcomes and commercial success. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-presents-precision-medicine-platforms-for-accelerated-pipeline-building-at-capital-markets-day-6346

Evotec SE today announced that the Company’s near-term emissions reduction targets have been approved by the Science Based Targets initiative (“SBTi”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-sbti-approval-for-its-near-term-emissions-reduction-targets-6342

Evotec SE today announced the financial results and corporate updates for the first nine months 2023. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-nine-months-2023-and-provides-corporate-update-6344

Evotec SE and Dewpoint Therapeutics today announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven platform (“INDiGO”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-dewpoint-therapeutics-enter-strategic-partnership-in-oncology-6340